摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-mercaptopropane-1,2-diyl dinitrate | 1316288-60-4

中文名称
——
中文别名
——
英文名称
(R)-3-mercaptopropane-1,2-diyl dinitrate
英文别名
——
(R)-3-mercaptopropane-1,2-diyl dinitrate化学式
CAS
1316288-60-4
化学式
C3H6N2O6S
mdl
——
分子量
198.156
InChiKey
JURUWVOVERWTAJ-GSVOUGTGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    12.0
  • 可旋转键数:
    6.0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    104.74
  • 氢给体数:
    1.0
  • 氢受体数:
    7.0

反应信息

  • 作为反应物:
    描述:
    (S)-4-(benzo[b]thiophen-2-yl)-1-(oxiran-2-ylmethyl)-1,2,3,6-tetrahydropyridine(R)-3-mercaptopropane-1,2-diyl dinitrate甲醇 为溶剂, 反应 3.0h, 以53%的产率得到(R)-3-((S)-3-(4-(benzo[b]thiophen-2-yl)-5,6-dihydropyridin-1(2H)-yl)-2-hydroxypropylthio)propane-1,2-diyl dinitrate
    参考文献:
    名称:
    NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor
    摘要:
    Hybrid nitrate drugs have been reported to provide NO bioactivity to ameliorate side effects or to provide ancillary therapeutic activity. Hybrid nitrate selective serotonin reuptake inhibitors (NO-SSRIs) were prepared to improve the therapeutic profile of this drug class. A synthetic strategy for use of a thiocarbamate linker was developed, which in the case of NO-fluoxetine facilitated hydrolysis to fluoxetine at pH 7.4 within 7 h. In cell culture, NO-SSRIs were weak inhibitors of the serotonin transporter; however, in the forced swimming task (FST) in rats, NO-fluoxetine demonstrated classical antidepressant activity. Comparison of NO-fluoxetine, with fluoxetine, and an NO-chimera nitrate developed for Alzheimer's disease (GT-1061) were made in the step through passive avoidance (STPA) test of learning and memory in rats treated with scopolamine as an amnesic agent. Fluoxetine was inactive, whereas NO-fluoxetine and GT-1061 both restored long-term memory. GT-1061 also produced antidepressant behavior in FST. These data support the potential for NO-SSRIs to overcome the lag in onset of therapeutic action and provide cotherapy of neuropathologies concomitant with depression.
    DOI:
    10.1021/ml2000033
点击查看最新优质反应信息